{
    "xml": "<topic id=\"PHP5660\" outputclass=\"drug\" rev=\"1.18\" type=\"drug\" namespace=\"/drugs/ofatumumab\" basename=\"ofatumumab\" title=\"OFATUMUMAB\">\n<title>OFATUMUMAB</title>\n<body>\r\n<p outputclass=\"interactionsLinks\"> List of individual interactants: <xref format=\"dita\" href=\"#bnf_int_1302\" namespace=\"/interactions/list-of-drug-interactions/cytotoxics/monoclonal-antibodies/ofatumumab\">Ofatumumab</xref>\n</p>\n<data name=\"vtmid\">444609007</data>\n<data name=\"classifications\">\n<data name=\"classification\">\n<data name=\"drugClassification\">\n<xref format=\"dita\" scope=\"local\" type=\"drugClassification\" href=\"#_872447286\" title=\"Monoclonal antibodies (antineoplastic)\">Monoclonal antibodies (antineoplastic)</xref>\n</data>\n<data name=\"inheritsFromClass\">\n<xref format=\"dita\" scope=\"local\" type=\"drugClass\" href=\"#PHP34582\" title=\"ANTI-LYMPHOCYTE MONOCLONAL ANTIBODIES\" namespace=\"/drug-classes/anti-lymphocyte-monoclonal-antibodies\">ANTI-LYMPHOCYTE MONOCLONAL ANTIBODIES</xref>\n</data>\n</data>\n</data>\n<data name=\"primaryDomainOfEffect\">\n<data name=\"domainOfEffect\">  </data>\n</data>\r\n</body>\n<topic id=\"PHP40192\" outputclass=\"indicationsAndDose\" rev=\"1.51\" parent=\"/drugs/ofatumumab\">\n<title>Indications and dose</title>\n<body>\n<section outputclass=\"indicationAndDoseGroup\">\n<sectiondiv outputclass=\"therapeuticIndications\">\n<p outputclass=\"therapeuticIndication\">Treatment of chronic lymphocytic leukaemia (CLL) in patients refractory to fludarabine and alemtuzumab</p>\n<p outputclass=\"therapeuticIndication\">Treatment of CLL in patients who have not received prior therapy and who are not eligible for fludarabine based therapy (in combination with chlorambucil or bendamustine)</p>\n</sectiondiv>\n<p outputclass=\"routesOfAdministration\">By intravenous infusion</p>\n<ul outputclass=\"patientGroups\">\n<li outputclass=\"patientGroup adult\">\n<p>Adult</p>\n<p>Premedication must be given 30 minutes to 2 hours before each dose&#8212;consult product literature for details.</p>\n</li>\n</ul>\n</section>\n</body>\n</topic>\n<topic id=\"PHP50571\" outputclass=\"contraindications\" rev=\"1.9\" parent=\"/drugs/ofatumumab\">\n<title>Contra-indications</title>\n<body>\n<section outputclass=\"importantAdvice\">\n<title>Contra-indications, further information</title>\n<sectiondiv>\n<p>For full details on the contra-indications for ofatumumab, consult product literature.</p>\n</sectiondiv>\n</section>\n</body>\n</topic>\n<topic id=\"PHP50637\" outputclass=\"cautions\" rev=\"1.28\" parent=\"/drugs/ofatumumab\">\n<title>Cautions</title>\n<body>\n<section outputclass=\"cautions\">\n<p>\n<ph outputclass=\"caution\">History of cardiac disease&#8212;monitor closely and discontinue treatment if cardiac arrhythmias occur</ph>\n</p>\n</section>\n<section outputclass=\"importantAdvice\">\n<title>Cautions, further information</title>\n<sectiondiv>\n<p outputclass=\"title\">Hepatitis B infection and reactivation</p>\n<p>Hepatitis B infection and reactivation (including fatal cases) have been reported in patients taking <b>ofatumumab</b>. Patients with positive hepatitis B serology should be referred to a liver specialist for monitoring and initiation of antiviral therapy before treatment initiation; treatment should not be initiated in patients with evidence of current hepatitis B infection until the infection has been adequately treated. Patients should be closely monitored for clinical and laboratory signs of active hepatitis B infection during treatment and for up to a year following the last infusion (consult product literature).</p>\n</sectiondiv>\n<sectiondiv>\n<p>For full details about the cautions for ofatumumab, consult product literature</p>\n</sectiondiv>\n</section>\n</body>\n</topic>\n<topic id=\"PHP40189\" outputclass=\"interactions\" rev=\"1.11\" parent=\"/drugs/ofatumumab\">\n<title>Interactions</title>\n<body>\n<section outputclass=\"general\">\n<sectiondiv>\n<p>Appendix 1 (ofatumumab).</p>\n</sectiondiv>\n</section>\n</body>\n</topic>\n<topic id=\"PHP40163\" outputclass=\"sideEffects\" rev=\"1.20\" parent=\"/drugs/ofatumumab\">\n<title>Side-effects</title>\n<body>\n<section outputclass=\"sideEffectsAdvice\">\n<title>Side-effects, further information</title>\n<sectiondiv>\n<p>For full details (including monitoring and management of side-effects) consult product literature.</p>\n</sectiondiv>\n<sectiondiv>\n<p>Infusion-related side-effects (including cytokine release syndrome) have been reported with ofatumumab; premedication with paracetamol, an antihistamine, and a corticosteroid must be given&#8212;consult product literature.</p>\n</sectiondiv>\n</section>\n</body>\n</topic>\n<topic id=\"PHP50603\" outputclass=\"conceptionAndContraception\" parent=\"/drugs/ofatumumab\">\n<title>Conception and contraception</title>\n<body>\n<section outputclass=\"generalInformation\">\n<sectiondiv>\n<p>Use effective contraception during and for 12 months after treatment.</p>\n</sectiondiv>\n</section>\n</body>\n</topic>\n<topic id=\"PHP40183\" outputclass=\"pregnancy\" parent=\"/drugs/ofatumumab\">\n<title>Pregnancy</title>\n<body>\n<section outputclass=\"generalInformation\">\n<sectiondiv>\n<p>Avoid unless potential benefit outweighs risk.</p>\n</sectiondiv>\n</section>\n</body>\n</topic>\n<topic id=\"PHP50680\" outputclass=\"breastFeeding\" parent=\"/drugs/ofatumumab\">\n<title>Breast feeding</title>\n<body>\n<section outputclass=\"generalInformation\">\n<sectiondiv>\n<p>Discontinue breast-feeding during and for 12 months after treatment&#8212;no information available.</p>\n</sectiondiv>\n</section>\n</body>\n</topic>\n<topic id=\"PHP40168\" outputclass=\"renalImpairment\" parent=\"/drugs/ofatumumab\">\n<title>Renal impairment</title>\n<body>\n<section outputclass=\"generalInformation\">\n<sectiondiv>\n<p>No information available for creatinine clearance less than 30&#8239;mL/minute.</p>\n</sectiondiv>\n</section>\n</body>\n</topic>\n<topic id=\"PHP40139\" outputclass=\"monitoringRequirements\" parent=\"/drugs/ofatumumab\">\n<title>Monitoring requirements</title>\n<body>\n<section outputclass=\"monitoringOfPatientParameters\">\n<sectiondiv>\n<p>Monitor electrolytes (including potassium and magnesium) before and during administration and correct if abnormal.</p>\n<p>Patients must be monitored closely during each infusion for the onset of infusion reactions.</p>\n</sectiondiv>\n</section>\n</body>\n</topic>\n<topic id=\"PHP40113\" outputclass=\"nationalFunding\" rev=\"1.22\" parent=\"/drugs/ofatumumab\">\n<title>National funding/access decisions</title>\n<body>\r\n<section>\r\n<sectiondiv outputclass=\"niceTechnologyAppraisals\">\r\n<p outputclass=\"title\">NICE technology appraisals (TAs)</p>\r\n<sectiondiv outputclass=\"niceTechnologyAppraisal\">\r\n<p outputclass=\"fundingIdentifier\">NICE TA202</p>\r\n<sectiondiv>\r\n<p outputclass=\"title\">Ofatumumab for the treatment of chronic lymphocytic leukaemia refractory to fludarabine and alemtuzumab (October 2010)</p>\r\n<p>Ofatumumab is <b>not</b> recommended for the treatment of chronic lymphocytic leukaemia that is refractory to fludarabine and alemtuzumab.</p>\r\n<p>Patients currently receiving ofatumumab for this condition should have the option to continue treatment until they and their clinician consider it appropriate to stop.</p>\n</sectiondiv>\n<xref format=\"html\" href=\"http://www.nice.org.uk/TA202\">www.nice.org.uk/TA202</xref>\n</sectiondiv>\r\n<sectiondiv outputclass=\"niceTechnologyAppraisal\">\r\n<p outputclass=\"fundingIdentifier\">NICE TA344</p>\r\n<sectiondiv>\r\n<p outputclass=\"title\">Ofatumumab in combination with chlorambucil or bendamustine for untreated chronic lymphocytic leukaemia (June 2015)</p>\r\n<p>Ofatumumab in combination with chlorambucil is an option for untreated chronic lymphocytic leukaemia only if:</p>\r\n<ul>\r\n<li>the person is ineligible for fludarabine-based therapy <b>and</b>\r\n</li>\r\n<li>bendamustine is not suitable<b> and</b>\r\n</li>\r\n<li>the manufacturer provides ofatumumab with the discount agreed in the patient access scheme.</li>\r\n</ul>\r\n<p>Patients currently receiving ofatumumab that is not recommended according to the above criteria should have the option to continue treatment until they and their clinician consider it appropriate to stop.</p>\n</sectiondiv>\n<xref format=\"html\" href=\"http://www.nice.org.uk/TA344\">www.nice.org.uk/TA344</xref>\n</sectiondiv>\n</sectiondiv>\r\n </section>\r\n\r\n</body>\n</topic>\n<topic id=\"PHP5660-medicinalForms\" outputclass=\"medicinalForms\" parent=\"/drugs/ofatumumab\">\n<title>Medicinal forms</title>\n<body>\n<section outputclass=\"licensingVariationStatement\">\n<p>There can be variation in the licensing of different medicines containing the same drug.</p>\n</section>\n</body>\n</topic>\n<parents>\n<xref format=\"dita\" scope=\"local\" type=\"drugs\" href=\"#drugs\" title=\"Drugs\" namespace=\"/drugs\">Drugs</xref>\n</parents>\n<children>\n<xref format=\"dita\" scope=\"local\" type=\"medicinalForm\" href=\"#PHP75288\" title=\"Solution for infusion\" namespace=\"/drugs/ofatumumab/solution-for-infusion\">Solution for infusion</xref>\n</children>\n<backlinks>\n<xref format=\"dita\" scope=\"local\" type=\"treatmentSummary\" href=\"#PHP107699\" namespace=\"/about/changes\" title=\"Changes\" count=\"1\" rel=\"backlink\">Changes</xref>\n<xref format=\"dita\" scope=\"local\" type=\"drugClassifications\" href=\"#PHP106980\" namespace=\"/drug-classifications\" title=\"Drug classifications\" count=\"1\" rel=\"backlink\">Drug classifications</xref>\n</backlinks>\n<links>\n<xref format=\"dita\" scope=\"local\" type=\"interaction\" href=\"#bnf_int_1302\" namespace=\"/interactions/list-of-drug-interactions/cytotoxics/monoclonal-antibodies/ofatumumab\" title=\"Ofatumumab\" count=\"1\" rel=\"link\">Ofatumumab</xref>\n<xref format=\"dita\" scope=\"local\" type=\"drugClass\" href=\"#PHP34582\" namespace=\"/drug-classes/anti-lymphocyte-monoclonal-antibodies\" title=\"ANTI-LYMPHOCYTE MONOCLONAL ANTIBODIES\" count=\"1\" rel=\"link\">ANTI-LYMPHOCYTE MONOCLONAL ANTIBODIES</xref>\n<xref format=\"dita\" scope=\"local\" type=\"#drugs\" href=\"#drugs\" namespace=\"/drugs\" title=\"Drugs\" count=\"1\" rel=\"link\">Drugs</xref>\n<xref format=\"dita\" scope=\"local\" type=\"medicinalForm\" href=\"#PHP75288\" namespace=\"/drugs/ofatumumab/solution-for-infusion\" title=\"Solution for infusion\" count=\"1\" rel=\"link\">Solution for infusion</xref>\n</links>\n</topic>",
    "id": "PHP5660",
    "outputclass": "drug",
    "rev": "1.18",
    "type": "drug",
    "namespace": "/drugs/ofatumumab",
    "basename": "ofatumumab",
    "title": "OFATUMUMAB",
    "interactants": [
        {
            "id": "bnf_int_1302",
            "label": "Ofatumumab"
        }
    ],
    "vtmid": "444609007",
    "drugClassification": [
        "Monoclonal antibodies (antineoplastic)"
    ],
    "inheritsFromClass": [
        "ANTI-LYMPHOCYTE MONOCLONAL ANTIBODIES"
    ],
    "primaryDomainOfEffect": {
        "": {
            "domain": "",
            "therapeuticUses": {}
        }
    },
    "indicationsAndDoses": {
        "indicationAndDoseGroups": [
            {
                "indications": [
                    {
                        "textContent": "Treatment of chronic lymphocytic leukaemia (CLL) in patients refractory to fludarabine and alemtuzumab",
                        "html": "Treatment of chronic lymphocytic leukaemia (CLL) in patients refractory to fludarabine and alemtuzumab"
                    },
                    {
                        "textContent": "Treatment of CLL in patients who have not received prior therapy and who are not eligible for fludarabine based therapy (in combination with chlorambucil or bendamustine)",
                        "html": "Treatment of CLL in patients who have not received prior therapy and who are not eligible for fludarabine based therapy (in combination with chlorambucil or bendamustine)"
                    }
                ],
                "specificity": {
                    "routes": [
                        "intravenous infusion"
                    ],
                    "textContent": "By intravenous infusion",
                    "html": "By intravenous infusion"
                },
                "adult": [
                    {
                        "textContent": "Premedication must be given 30 minutes to 2 hours before each dose&#8212;consult product literature for details.",
                        "html": "<p>Premedication must be given 30 minutes to 2 hours before each dose&#8212;consult product literature for details.</p>"
                    }
                ]
            }
        ]
    },
    "contraindications": {
        "importantAdvice": [
            {
                "type": "importantAdvice",
                "textContent": "For full details on the contra-indications for ofatumumab, consult product literature.",
                "html": "<p>For full details on the contra-indications for ofatumumab, consult product literature.</p>"
            }
        ]
    },
    "cautions": {
        "cautions": [
            {
                "type": "cautions",
                "textContent": "History of cardiac disease&#8212;monitor closely and discontinue treatment if cardiac arrhythmias occur",
                "html": "History of cardiac disease&#8212;monitor closely and discontinue treatment if cardiac arrhythmias occur"
            }
        ],
        "importantAdvice": [
            {
                "type": "importantAdvice",
                "title": "Hepatitis B infection and reactivation",
                "textContent": "Hepatitis B infection and reactivation (including fatal cases) have been reported in patients taking ofatumumab. Patients with positive hepatitis B serology should be referred to a liver specialist for monitoring and initiation of antiviral therapy before treatment initiation; treatment should not be initiated in patients with evidence of current hepatitis B infection until the infection has been adequately treated. Patients should be closely monitored for clinical and laboratory signs of active hepatitis B infection during treatment and for up to a year following the last infusion (consult product literature).",
                "html": "<p>Hepatitis B infection and reactivation (including fatal cases) have been reported in patients taking <b>ofatumumab</b>. Patients with positive hepatitis B serology should be referred to a liver specialist for monitoring and initiation of antiviral therapy before treatment initiation; treatment should not be initiated in patients with evidence of current hepatitis B infection until the infection has been adequately treated. Patients should be closely monitored for clinical and laboratory signs of active hepatitis B infection during treatment and for up to a year following the last infusion (consult product literature).</p>"
            },
            {
                "type": "importantAdvice",
                "textContent": "For full details about the cautions for ofatumumab, consult product literature",
                "html": "<p>For full details about the cautions for ofatumumab, consult product literature</p>"
            }
        ]
    },
    "interactions": {
        "general": [
            {
                "type": "general",
                "textContent": "Appendix 1 (ofatumumab).",
                "html": "<p>Appendix 1 (ofatumumab).</p>"
            }
        ]
    },
    "sideEffects": {
        "advice": [
            {
                "type": "advice",
                "textContent": "For full details (including monitoring and management of side-effects) consult product literature.",
                "html": "<p>For full details (including monitoring and management of side-effects) consult product literature.</p>"
            },
            {
                "type": "advice",
                "textContent": "Infusion-related side-effects (including cytokine release syndrome) have been reported with ofatumumab; premedication with paracetamol, an antihistamine, and a corticosteroid must be given&#8212;consult product literature.",
                "html": "<p>Infusion-related side-effects (including cytokine release syndrome) have been reported with ofatumumab; premedication with paracetamol, an antihistamine, and a corticosteroid must be given&#8212;consult product literature.</p>"
            }
        ]
    },
    "conceptionAndContraception": {
        "generalInformation": [
            {
                "type": "generalInformation",
                "textContent": "Use effective contraception during and for 12 months after treatment.",
                "html": "<p>Use effective contraception during and for 12 months after treatment.</p>"
            }
        ]
    },
    "pregnancy": {
        "generalInformation": [
            {
                "type": "generalInformation",
                "textContent": "Avoid unless potential benefit outweighs risk.",
                "html": "<p>Avoid unless potential benefit outweighs risk.</p>"
            }
        ]
    },
    "breastFeeding": {
        "generalInformation": [
            {
                "type": "generalInformation",
                "textContent": "Discontinue breast-feeding during and for 12 months after treatment&#8212;no information available.",
                "html": "<p>Discontinue breast-feeding during and for 12 months after treatment&#8212;no information available.</p>"
            }
        ]
    },
    "renalImpairment": {
        "generalInformation": [
            {
                "type": "generalInformation",
                "textContent": "No information available for creatinine clearance less than 30 mL/minute.",
                "html": "<p>No information available for creatinine clearance less than 30&#8239;mL/minute.</p>"
            }
        ]
    },
    "monitoringRequirements": {
        "patientParameters": [
            {
                "type": "patientParameters",
                "textContent": "Monitor electrolytes (including potassium and magnesium) before and during administration and correct if abnormal.\n\nPatients must be monitored closely during each infusion for the onset of infusion reactions.",
                "html": "<p>Monitor electrolytes (including potassium and magnesium) before and during administration and correct if abnormal.</p><p>Patients must be monitored closely during each infusion for the onset of infusion reactions.</p>"
            }
        ]
    },
    "nationalFunding": {
        "niceTechnologyAppraisals": [
            {
                "type": "niceTechnologyAppraisals",
                "references": [
                    {
                        "id": "http://www.nice.org.uk/TA202",
                        "label": "www.nice.org.uk/TA202"
                    }
                ],
                "fundingIdentifier": "NICE TA202",
                "textContent": "Ofatumumab for the treatment of chronic lymphocytic leukaemia refractory to fludarabine and alemtuzumab (October 2010) Ofatumumab is not recommended for the treatment of chronic lymphocytic leukaemia that is refractory to fludarabine and alemtuzumab. Patients currently receiving ofatumumab for this condition should have the option to continue treatment until they and their clinician consider it appropriate to stop.\n\nwww.nice.org.uk/TA202",
                "html": "<p outputclass=\"title\">Ofatumumab for the treatment of chronic lymphocytic leukaemia refractory to fludarabine and alemtuzumab (October 2010)</p> <p>Ofatumumab is <b>not</b> recommended for the treatment of chronic lymphocytic leukaemia that is refractory to fludarabine and alemtuzumab.</p> <p>Patients currently receiving ofatumumab for this condition should have the option to continue treatment until they and their clinician consider it appropriate to stop.</p><xref format=\"html\" href=\"http://www.nice.org.uk/TA202\">www.nice.org.uk/TA202</xref>"
            },
            {
                "type": "niceTechnologyAppraisals",
                "references": [
                    {
                        "id": "http://www.nice.org.uk/TA344",
                        "label": "www.nice.org.uk/TA344"
                    }
                ],
                "fundingIdentifier": "NICE TA344",
                "textContent": "Ofatumumab in combination with chlorambucil or bendamustine for untreated chronic lymphocytic leukaemia (June 2015) Ofatumumab in combination with chlorambucil is an option for untreated chronic lymphocytic leukaemia only if: the person is ineligible for fludarabine-based therapy and bendamustine is not suitable and the manufacturer provides ofatumumab with the discount agreed in the patient access scheme. Patients currently receiving ofatumumab that is not recommended according to the above criteria should have the option to continue treatment until they and their clinician consider it appropriate to stop.\n\nwww.nice.org.uk/TA344",
                "html": "<p outputclass=\"title\">Ofatumumab in combination with chlorambucil or bendamustine for untreated chronic lymphocytic leukaemia (June 2015)</p> <p>Ofatumumab in combination with chlorambucil is an option for untreated chronic lymphocytic leukaemia only if:</p> <ul> <li>the person is ineligible for fludarabine-based therapy <b>and</b> </li> <li>bendamustine is not suitable<b> and</b> </li> <li>the manufacturer provides ofatumumab with the discount agreed in the patient access scheme.</li> </ul> <p>Patients currently receiving ofatumumab that is not recommended according to the above criteria should have the option to continue treatment until they and their clinician consider it appropriate to stop.</p><xref format=\"html\" href=\"http://www.nice.org.uk/TA344\">www.nice.org.uk/TA344</xref>"
            }
        ]
    },
    "medicinalForms": {
        "licensingVariationStatement": [
            {
                "type": "licensingVariationStatement",
                "textContent": "There can be variation in the licensing of different medicines containing the same drug.",
                "html": "<p>There can be variation in the licensing of different medicines containing the same drug.</p>"
            }
        ]
    },
    "children": {
        "medicinalForm": [
            {
                "id": "PHP75288",
                "label": "Solution for infusion",
                "type": "medicinalForm"
            }
        ]
    },
    "backlinks": {
        "treatmentSummary": [
            {
                "id": "PHP107699",
                "label": "Changes",
                "type": "treatmentSummary"
            }
        ],
        "drugClassifications": [
            {
                "id": "PHP106980",
                "label": "Drug classifications",
                "type": "drugClassifications"
            }
        ]
    },
    "links": {
        "interaction": [
            {
                "id": "bnf_int_1302",
                "label": "Ofatumumab",
                "type": "interaction"
            }
        ],
        "drugClass": [
            {
                "id": "PHP34582",
                "label": "ANTI-LYMPHOCYTE MONOCLONAL ANTIBODIES",
                "type": "drugClass"
            }
        ],
        "#drugs": [
            {
                "id": "drugs",
                "label": "Drugs",
                "type": "#drugs"
            }
        ],
        "medicinalForm": [
            {
                "id": "PHP75288",
                "label": "Solution for infusion",
                "type": "medicinalForm"
            }
        ]
    }
}